Ophthalmic delivery of brinzolamide by liquid crystalline nanoparticles: In vitro and in vivo evaluation

AAPS PharmSciTech

Volumn 14, Issue 3, 2013, Pages 1063-1071

  Wu, Weijun ^a   Li, Jing ^a   Wu, Lin ^a   Wang, Baoyan ^a   Wang, Zhongyuan ^a   Xu, Qunwei ^a   Xin, Hongliang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

brinzolamide; liquid crystalline nanoparticles; ocular bioavailability; ocular irritation; ophthalmic delivery

Indexed keywords

BRINZOLAMIDE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CORNEA PERMEABILITY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EMULSION; ENCAPSULATION; EYE IRRITATION; GLAUCOMA; INTRAOCULAR PRESSURE; LIQUID CRYSTAL; MEAN RESIDENCE TIME; NANOPHARMACEUTICS; NONHUMAN; OPHTHALMIC DRUG DELIVERY DEVICE; OSMOLALITY; PARTICLE SIZE; PATIENT COMPLIANCE; PH; PRIORITY JOURNAL; RABBIT; TRANSMISSION ELECTRON MICROSCOPY; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, OPHTHALMIC; ANIMALS; CARBONIC ANHYDRASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORNEA; CRYSTALLIZATION; INTRAOCULAR PRESSURE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; RABBITS; SCATTERING, SMALL ANGLE; SULFONAMIDES; THIAZINES;

EID: 84890222154     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-013-9997-2     Document Type: Article

References (36)

1. Quigley H, Broman A. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-7.
2. Becher B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor, Diamox: a preliminary report. Am J Ophthalmol. 1954;37:13-5.
3. Silver LH. Clinical efficacy and safety of brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol. 1998;126:400-8.
4. Michaud J, Friren B. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:235.
5. March WF, Ochsner KI. The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2000;129:136-43.
6. Shin D. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt®) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol. 2000;44:S163-8.
7. Meisner D, Mezei M. Liposome ocular delivery systems. Adv Drug Deliv Rev. 1995;16:75-93.
8. Zimmer A, Kreuter J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev. 1995;16:61-73.
9. Yamaguchi M, Yasueda S, Isowaki A, Yamamoto M, Kimura M, Inada K, et al. Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharm. 2005;301:121-8.
10. Han S, Shen J, Gan Y, Geng H, Zhang X, Zhu C, et al. Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability. Acta Pharmacol Sin. 2010;31:990-8.
11. Esposito E, Cortesi R, Drechsler M, Paccamiccio L, Mariani P, Contado C, et al. Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm Res. 2005;22:2163-73.
12. Hirlekar R, Jain S, Patel M, Garse H, Kadam V. Hexosomes: a novel drug delivery system. Curr Drug Deliv. 2010;7:28.
13. Lopes LB, Ferreira DA, de Paula D, Garcia MTJ, Thomazini JA, Fantini MCA, et al. Reverse hexagonal phase nanodispersion of monoolein and oleic acid for topical delivery of peptides: in vitro and in vivo skin penetration of cyclosporin A. Pharm Res. 2006;23:1332-42.
14. Swarnakar NK, Jain V, Dubey V, Mishra D, Jain N. Enhanced oromucosal delivery of progesterone via hexosomes. Pharm Res. 2007;24:2223-30.
15. Boyd BJ, Whittaker DV, Khoo SM, Davey G. Hexosomes formed from glycerate surfactants - formulation as a colloidal carrier for irinotecan. Int J Pharm. 2006;318:154-62.
16. Amar-Yuli I, Wachtel E, Shoshan EB, Danino D, Aserin A, Garti N. Hexosome and hexagonal phases mediated by hydration and polymeric stabilizer. Langmuir. 2007;23:3637-45.
17. 5] enkephalin from liquid crystalline phases of glyceryl monooleate. Int J Pharm. 2000;195:35-8.
18. 5] enkephalin from a cubic phase of glyceryl monooleate. Int J Pharm. 2000;204:137-44.
19. Gan L, Han S, Shen J, Zhu J, Zhu C, Zhang X, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Int J Pharm. 2010;396:179-87.
20. Hägerström H, Paulsson M, Edsman K. Evaluation of mucoadhesion for two polyelectrolyte gels in simulated physiological conditions using a rheological method. Eur J Pharm Sci. 2000;9:301-9.
21. Ye J, Wang Q, Zhou X, Zhang N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int J Pharm. 2008;352:273-9.
22. Huo D, Deng S, Li L, Ji J. Studies on the poly(lactic-co-glycolic) acid microspheres of cisplatin for lung-targeting. Int J Pharm. 2005;289:63-7.
23. Suhonen P, Jarvinen T, Peura P, Urtti A. Permeability of pilocarpic acid diesters across albino rabbit cornea in vitro. Int J Pharm. 1991;74:221-8.
24. Liu J, Fu S, Wei N, Hou Y, Zhang X, Cui H. The effects of combined menthol and borneol on fluconazole permeation through the cornea ex vivo. Eur J Pharmacol. 2012;688:1-5.
25. Ammar HO, Salama H, Ghorab M, Mahmoud A. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech. 2009;10:808-19.
26. Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82:377-90.
27. Das S, Suresh PK, Desmukh R. Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine. 2010;6:318-23.
28. Palma SD, Tartara LI, Quinteros D, Allemandi DA, Longhi MR, Granero GE. An efficient ternary complex of acetazolamide with HP-ss-CD and TEA for topical ocular administration. J Control Release. 2009;138:24-31.
29. Seddon JM. Structure of the inverted hexagonal (H II) phase, and non-lamellar phase transitions of lipids. Biochim Biophys Acta. 1990;1031:1-69.
30. Monduzzi M, Ljusberg-Wahren H, Larsson K. A 13C NMR study of aqueous dispersions of reversed lipid phases. Langmuir. 2000;16:7355-8.
31. Libster D, Ishai PB, Aserin A, Shoham G, Garti N. Molecular interactions in reverse hexagonal mesophase in the presence of Cyclosporin A. Int J Pharm. 2009;367(1):115-26.
32. Barauskas J, Cervin C, Jankunec M, Špandyreva M, Ribokaite K, Tiberg F, et al. Interactions of lipid-based liquid crystalline nanoparticles with model and cell membranes. Int J Pharm. 2010;391:284-91.
33. Taskovich LT. Skin permeation enhancer compositions using glycerol monooleate. Google Patents. 1989.
34. Saettone MF, Chetoni P, Cerbai R, Mazzanti G, Braghiroli L. Evaluation of ocular permeation enhancers: in vitro effects on corneal transport of four β-blockers, and in vitro/in vivo toxic activity. Int J Pharm. 1996;142:103-13.
35. Akman A, Cetinkaya A, Akova Y, Ertan A. Comparison of additional intraocular pressure-lowering effects of latanoprost vs brimonidine in primary open-angle glaucoma patients with intraocular pressure uncontrolled by timolol-dorzolamide combination. Eye. 2004;19:145-51.
36. Boyd BJ, Whittaker DV, Khoo SM, Davey G. Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems. Int J Pharm. 2006;309:218-26.